A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Regulatory T cells (Tregs) expressing CC chemokine receptor 4 (CCR4) can suppress antitumor immune responses and are associated with poor prognoses in several cancers. We assessed the safety and efficacy of combined mogamulizumab (anti-CCR4 antibody) and nivolumab [anti-programmed death-1 (PD-1) antibody] in immunotherapy-naïve patients with advanced/metastatic solid tumors.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Cancer Res

Title: Clinical cancer research : an official journal of the American Association for Cancer Research

Publisher: American Association for Cancer Research (AACR)

ISSN (Electronic): 1557-3265

ISSN (Print): 1078-0432

Publication date (Electronic): November 15 2019

Volume: 25

Issue: 22

Affiliations

[1 ] Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan. tdoi@east.ncc.go.jp.

[2 ] Clinical Oncology and Outpatient Treatment Center, Aichi Cancer Center Hospital, Nagoya, Japan.

[3 ] Clinical Research Center, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.

[4 ] Division of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.

[5 ] Division of GI Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

[6 ] Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.

[7 ] Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.

[8 ] Oncology Clinical Development Unit, Ono Pharmaceutical Co., Ltd., Osaka, Japan.

[9 ] R&D Division, Kyowa Kirin Co., Ltd., Tokyo, Japan.

[10 ] Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

[11 ] Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Japan.

[12 ] Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.

Article

Publisher Item ID: 1078-0432.CCR-19-1090

DOI: 10.1158/1078-0432.CCR-19-1090

PubMed ID: 31455681

SO-VID: d33fa440-0a3f-4514-887c-493b27d63d11

History

Data availability:

Comments

Comment on this article

scite_

Cited by 72

See all cited by

- Version 1